Nymox Pharmaceutical Corporation news

   Watch this stock
Showing stories 1 - 10 of about 81   

Articles published

NYMX 2.64 +0.02 (0.76%)
price chart
Here's Why Nymox Pharmaceutical Corporation (NYMX) Stock Gained More Than 100%
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) announced the results of its long-term extension prospective, double-blind pivotal Phase 3 research today.
Can Nymox Sustain This Massive Rally?  24/7 Wall St.
Nymox Pharmaceutical Corporation (NYMX) Jumps On News Of Study Results  Insider Monkey (blog)
Healthcare Stocks In Focus- Nymox Pharmaceutical Corporation (NASDAQ:NYMX ...
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) reported that the firm has newly designated James G. Robinson to the Board of Directors.
Overbought Stocks: Inotek Pharmaceuticals Corp (NASDAQ:ITEK), Nymox ...
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) has a RSI reading of 86.42, with a 1-year total return of -45.05% and a six-month return of 554.16%.
Stocks Reached An Overbought Condition: Nymox Pharmaceutical Corporation ...
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is now in overbought territory with an RSI value of 81.04. The stock is up 96.99% in one month through last close, to $2.62, showing a 111.29% return during the past three months.
Active Stocks Trader's Buzzers: Verizon Communications Inc. (NYSE:VZ), Nymox ...
On July 15, 2015, the Board of Directors of Nymox Pharmaceutical Corporation approved the engagement of Cutler & Co., LLC to serve as the Company's new independent registered public accounting firm to replace KPMG LLP.
Class Action Lawsuit Filed Against Nymox Pharmaceutical Corporation and Paul ...
PHILADELPHIA, Nov. 25, 2014 (GLOBE NEWSWIRE) -- Law Offices Bernard M. Gross, P.C. filed a class action lawsuit in the United States District Court, District of New Jersey, 14-cv-07331, on behalf of purchasers of NYMOX common stock between January ...
Related articles »  
Cohen, Placitella & Roth, PC Investigating Nymox Pharmaceutical Corporation ...
26, 2014 /PRNewswire/ -- Cohen, Placitella & Roth, PC is investigating potential claims on behalf of investors who purchased Nymox Pharmaceutical Corporation ("Nymox" or "Company") NYMX, -5.88% during the period from January 31, 2011 through ...
Related articles »  
Is Nymox a Fluke or Is It Back?
Nymox Pharmaceutical Corp. (NASDAQ: NYMX) has been around for a long time, but within the past five years the stock has literally fallen off a cliff.
Here's Why Nymox Nosedived Yesterday
Nymox Pharmaceutical Corporation (NYMX) was one of the biggest losers in the biotech sector yesterday, as its stock plunged almost 82% on news that the company's key drug candidate was unsuccessful in two late-stage trials.
Nymox Pharma (NYMX) Phase 3 Studies of NX-1207 Fail to Meet Primary Endpoints  StreetInsider.com (subscription)
Nymox NX-1207 BPH Pivotal Phase 3 U.S. Studies NX02-0017 and NX02-0018 Fail ...  GlobeNewswire (press release)
Related articles »  
Nymox Pharma (NYMX) Reports No Top-Line Statistical Significance in NX-1207 ...
Nymox Pharmaceutical Corporation (Nasdaq: NYMX) announced today that the Company is undertaking further analyses of its pivotal U.S.
Nymox Announces Phase 3 BPH Studies  GlobeNewswire (press release)